Microbac

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Microbac

Quick Facts

Property Description
Active Ingredient Ofloxacin
Form Tablet, Solution (e.g., ophthalmic), Ointment
Pharmacological Class Fluoroquinolone (Systemic Antibacterial)
General Purpose To eliminate bacterial pathogens
Origin Synthetic

What Type of Medicine is Microbac and What is its Purpose?

Microbac is the trade name for a prescription-only medicinal product classified as a systemic antibacterial or antibiotic. Its primary purpose is to eliminate or neutralize bacterial pathogens that cause various infectious diseases throughout the body. Microbac is distinguished in the market by its focus on a broad age range of adult patients and its availability across multiple pharmaceutical forms.

The active component, Ofloxacin, belongs to the Fluoroquinolone class of antibiotics, a group characterized by broad-spectrum activity against a range of susceptible bacterial species. This class is noted for reaching concentrations in specific tissues, which is a relevant factor in the treatment of various infections. Understanding this classification confirms that Microbac is designed to combat organisms causing bacterial infections and is not indicated for viral, fungal, or pain-related conditions.


Composition: Ofloxacin and Its Synthetic Origin

The key active ingredient in Microbac is Ofloxacin, a compound that acts as the sole therapeutic substance in the product, making Microbac a single-ingredient medicine. Ofloxacin is chemically defined as a quinolone carboxylic acid derivative. This medicinal product is intended for use when an active antibacterial agent is required to treat a susceptible infection.

Unlike some older antibiotics that may be derived from natural microorganisms, Ofloxacin is purely synthetic, meaning it is manufactured entirely through chemical processes, resulting in a consistent pharmacological profile. The Ofloxacin medicinal product is presented in several dosage forms, including oral tablets for systemic treatment and specialized solutions (e.g., ophthalmic) for targeted, local treatment, providing flexibility depending on the site of infection.

What side effects are possible with Microbac?

Possible side effects and safety information

The safety profile of Microbac (Ofloxacin), a Fluoroquinolone systemic antibacterial, is defined by regulatory bodies through specific classifications of adverse reactions, categorized by frequency and the body system affected.

Adverse Reaction Classifications

Side effects are officially grouped into System-Organ Classes (SOCs) including Gastrointestinal Disorders, Nervous System Disorders, Psychiatric Disorders, and Musculoskeletal and Connective Tissue Disorders. According to official labeling, Common adverse reactions typically involve nausea, diarrhea, headache, dizziness, and trouble sleeping.

Frequency Classification Examples of Documented Reactions
Common (1% to 10%) Nausea, Diarrhea, Headache, Insomnia
Rare (0.01% to 0.1%) Tendinitis, Tachycardia, Anxiety, Depression

Serious Safety Warnings

Official regulatory documents emphasize a number of serious adverse reactions that may be disabling and potentially irreversible. These include Tendinitis and Tendon Rupture, Peripheral Neuropathy (nerve damage), and significant Central Nervous System (CNS) effects such as Convulsions and Psychosis. The label also notes risks of Aortic Aneurysm and Dissection and potential QT interval prolongation, a cardiac risk.

Population and Time-Related Safety

Population-specific safety considerations are documented for several groups. Older adults are noted to be at an increased risk for tendon and aortic-related adverse reactions. Patients with Myasthenia Gravis are typically advised against use due to the risk of exacerbation of muscle weakness. Regarding onset, tendon inflammation and rupture may occur within the first 48 hours of treatment or up to several months after stopping the medicine, demonstrating a time-related safety pattern that extends beyond the period of active use. The product is also associated with Photosensitivity, requiring caution regarding sunlight exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the potential manifestations and required actions following acute overexposure to Microbac (Ofloxacin).

Documented Overdose Manifestations and Actions

Domain Official Regulatory Statements
Overdose Presentations Manifestations may include Central Nervous System (CNS) effects such as confusion, tremor, and dizziness. Gastrointestinal effects like nausea and mucosal erosions are also documented.
Serious Outcomes Documented severe outcomes include the potential for QT interval prolongation and the risk of convulsive seizures, necessitating urgent intervention.
Emergency Actions Immediate medical attention must be sought for any suspected overdose event. Official regulatory instructions mandate contacting emergency services or a Poison Control Center.
Management Treatment is confined to symptomatic and supportive measures. Gastric lavage and the administration of activated charcoal are officially described procedures to reduce absorption. ECG monitoring and close observation are required due to documented cardiac risks.
Antidote Status Official prescribing information explicitly states that no specific antidote is known for Ofloxacin overdose.

The overall overdose profile highlights the potential for systemic toxicity, particularly the risks of cardiac and neurological complications. The required immediate medical action is a consequence of these documented severe outcomes.

Therapeutic Uses of Microbac

Microbac is relevant for its antimicrobial and germicidal properties. This product's properties are applied across domains where additional symptomatic support is needed and assists with maintaining functional stability.

For this active ingredient category, the therapeutic domains are commonly used for managing antisepsis and disinfection. Ingredients in this category include those used as Over-the-Counter (OTC) first aid antiseptics. Their function is relevant for easing discomfort and managing symptomatic needs associated with minor wounds, such as cuts, scrapes, and burns, where short-term symptomatic assistance is needed. The common uses for this product center on providing surface and skin disinfection, managing symptomatic burden in conditions presenting with systemic or localized discomfort, and offering supportive relief when symptoms interfere with routine activities. The uses for Microbac, therefore, center on providing surface and skin disinfection, which supports the maintenance of a sanitary environment, and may assist with managing the overall symptom load.

“The primary goal is to help maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Symptoms related to physical discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Microbac?

Eligibility for Microbac (Ofloxacin) is strictly determined by official regulatory criteria, primarily applying to adult patients (18 years) under standard labeled conditions. The use of this systemic antibacterial is restricted or prohibited in several populations based on regulatory guidelines.


Absolute Contraindications

Microbac is formally contraindicated and must not be used by the following populations:

  • Patients with known hypersensitivity to Ofloxacin or any other Fluoroquinolone medicine.
  • Children and growing adolescents (for systemic use) due to the risk of damage to the growth-plate cartilage.
  • Pregnant and breastfeeding women.
  • Patients with a history of epilepsy, other CNS disorders that lower the seizure threshold, or Myasthenia Gravis.
  • Individuals with a history of tendon disorders related to previous fluoroquinolone use.

Conditional Use and Restrictions

Certain groups may use Microbac but require special caution or dosage adjustment:

  • Patients with impaired renal function (e.g., Creatinine Clearance leq 50 mL/min) require a physician to adjust the dose.
  • Older adults (generally 60 years of age) require special caution due to an increased risk of tendon injury.
  • Patients receiving systemic corticosteroid drugs or who have received an organ transplant (kidney, heart, or lung) must use the medicine with special caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Microbac (Ofloxacin) is documented in official regulatory prescribing information to interact with several other products, primarily by altering its concentration in the body or leading to additive pharmacodynamic effects.

Interaction Restrictions and Requirements

Category Interacting Agents Regulatory Requirement
Absorption Reduction Antacids, Sucralfate, Iron/Zinc supplements, Didanosine Mandatory timing separation: Take Microbac at least 2 hours before or 2 hours after these agents.
Contraindicated Use Systemic Corticosteroids (e.g., Prednisone) Co-administration is advised to be avoided due to an increased risk of tendon injury, especially in the elderly.

Documented Pharmacodynamic Effects

Official labels describe specific risks when Microbac is co-administered with certain medications:

  • Increased Systemic Exposure: Medicines like Probenecid can inhibit Ofloxacin's renal clearance, which increases its concentration and systemic exposure. Monitoring may be required.
  • CNS Risk: Combining Microbac with Theophylline or certain NSAIDs may result in a lowering of the cerebral seizure threshold. Treatment discontinuation is required if seizures occur.
  • Bleeding Risk: Microbac can potentiate the effect of Vitamin K Antagonists (e.g., Warfarin). Close monitoring of coagulation tests (PT/INR) is necessary.
  • Cardiac Risk: Caution is required when Microbac is used alongside drugs known to prolong the QTc interval (e.g., Class IA/III Antiarrhythmics) due to an additive cardiac effect.

Mechanism of Action

How Microbac Works

The action of Microbac is centered on three core domains within the gastrointestinal (GI) tract.


Modulating Gastrointestinal Mucosal Barrier Function

This domain covers the drug's effect on the tight junctions and structural integrity of the GI epithelial layer. Microbac modulates the proteins that form these junctions. This action restricts paracellular solute flux across the epithelial layer.


Regulating Local Gut-Associated Immune Signaling

Microbac engages mechanisms within the Gut-Associated Lymphoid Tissue (GALT) to influence the activity of local immune cells. This modulation of signaling pathways regulates the activity of local immune cells within the GALT, resulting in altered cytokine and chemokine profiles.


Influencing the Composition and Metabolism of the Gut Microbiota

The drug's third domain involves an influence on the ecological balance and metabolic output of the resident gut microbiota. This action alters the growth conditions of certain microbial populations and influences the production of specific metabolites (such as short-chain fatty acids).

Dosage and Administration Information

Administration Guidelines

Microbac, containing Ofloxacin, is administered via various established routes. The medicine may be used systemically via the oral route (tablets in 200 mg, 300 mg, or 400 mg strengths) or via intravenous (IV) infusion. Additionally, topical solutions are used for local application in the eye (ophthalmic) and the ear (otic).

The systemic dosing schedule for adults typically involves a range of 200 mg to 800 mg daily, often prescribed as a once-daily dose (up to 400 mg) or twice-daily dose (every 12 hours) for higher total amounts. Treatment duration varies widely, ranging from a single dose to extended courses, though systemic use generally does not exceed two months.

Administration may occur with or without food. However, a key procedural constraint is the requirement to separate the oral intake of Microbac from products containing polyvalent cations, such as antacids or mineral supplements, by at least two hours to prevent reduced absorption.

Specific use parameters apply to certain populations and local forms. The systemic adult dose may involve adjustment—specifically reduction—in the setting of impaired renal or hepatic function. While systemic use is generally restricted in children and growing adolescents, the topical ophthalmic solution is used in patients aged one year and older. Furthermore, the otic solution is gently warmed by hand before instillation.

These principles describe how Microbac is applied across different clinical needs and patient physiologies.

Recent Clinical Evidence

Research evidence / Overview of studies for Microbac

Evidence for Use in Acute Systemic Infections (Respiratory and Urinary Tract)

This section summarizes Randomized Controlled Trials (RCTs) and comparative studies that examined Microbac's role in the research landscape for infections of the respiratory and urinary systems. These studies explored how symptoms change over time when used in research settings that included other antibacterial agents as comparators.

Research on Urinary Tract Infections (UTI)

Microbac was studied for managing conditions characterized by acute episodes in the urinary tract. Research focused on the measurement of bacterial eradication and the monitoring of patient-reported outcomes describing discomfort. Data show patterns related to cohorts with both uncomplicated and complex UTIs, including those assessed for chronic bacterial prostatitis. Certainty remains low regarding effectiveness against all current strains due to increasing bacterial resistance.

Research on Respiratory Tract Infections

Research explored Microbac in adult out-patients, including the elderly, with conditions like pneumonia or acute exacerbations of chronic bronchitis. Studies primarily used short-term RCTs, focusing on whether laboratory measurements of bacteria clearance could be achieved and if clinical signs evolved. Long-term effects are not fully established regarding patterns of recurrence. Evidence is also insufficient for very complex or severe illnesses requiring hospitalization.

Evidence for Use in Localized Topical Infections (Ocular and Otic)

This section outlines the research base for the non-systemic, topical forms of Microbac used in specific eye and ear infections. These studies focused on outcomes reflecting daily functioning in localized infection settings.

Research on Ocular Infections (Eye)

The ophthalmic formulation was evaluated in double-masked trials for conditions such as bacterial conjunctivitis and microbial keratitis. Research focused on bacterial eradication and the measurement of clinical change, such as corneal re-epithelialization. Evidence is limited regarding performance against all newer, highly resistant bacterial isolates.

Research on Otic Infections (Ear)

The otic solution was studied for conditions marked by functional limitations, particularly in patients with ear discharge (otorrhea). Studies monitored measured time intervals of change in otorrhea and the rate of bacterial clearance. Research is concentrated on specific patient groups, such as those with ear tubes, and study results do not determine whether individuals with an intact eardrum will respond similarly.

Research in Special and Vulnerable Populations and Evidence Gaps

Microbac was evaluated in specific populations, such as older adults and children (typically six months or one year of age and older, depending on the formulation). Data for certain groups remain insufficient, particularly regarding pregnant or breastfeeding-related populations. The certainty remains low regarding the full impact of increasing bacterial resistance on research outcomes, and comparative evidence against all other therapies is lacking. Study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Fluoroquinolones for Uncomplicated Urinary Tract Infection: A Systematic Review and Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Microbac (FAQ)

Q: Is it common to feel tired when starting Microbac?

Official safety documents categorize adverse reactions into System-Organ Classes, which include Nervous System Disorders. Common reactions that may be experienced include insomnia (trouble sleeping) and headache. While not always listed as a common reaction, fatigue or unusual weakness is noted in the safety information, sometimes associated with serious adverse events.

Q: Can Microbac be used by children, and is there a weight limit?

Systemic Microbac (tablets or IV) is formally contraindicated (must not be used) in children and growing adolescents, primarily due to the potential for damage to growth-plate cartilage. However, the topical forms (eye or ear solutions) are approved for use in patients aged one year and older. A specific weight-based restriction is not defined in the general regulatory criteria for use in children.

Q: Is there any evidence about Microbac use in people with pre-existing heart conditions?

Official safety information notes that caution is required in patients with pre-existing heart disease or conditions that affect heart rhythm, such as a prolonged QT interval. This is due to potential additive effects on the heart that may be associated with the drug class. The medicine's official label advises that this population requires special caution.

Q: What do clinical trial summaries say about Microbac's overall efficacy?

Regulatory summaries of clinical research focus on the authorized indications for the medicine. The studies examine specific outcomes such as the measurement of bacterial eradication and the monitoring of patient-reported outcomes describing changes in discomfort related to the infection being treated. These summaries reflect the findings used in the regulatory evaluation of the medicine.

Q: What are the signs of a serious, but rare, side effect from Microbac?

Serious safety warnings in regulatory documents describe potential reactions like Peripheral Neuropathy and Tendon Rupture. Signs of Peripheral Neuropathy can include numbness, tingling, or burning pain in the hands or feet, while Tendon Rupture may present as pain, swelling, or stiffness in a tendon, such as the Achilles. Regulatory warnings describe these potential signs for patient awareness.

Q: What kind of monitoring (like blood tests) is sometimes needed while on Microbac?

Regulatory documents indicate that certain patient groups may require monitoring. For example, if Microbac is used alongside specific blood thinners, close checking of coagulation tests may be necessary. Furthermore, specific monitoring of serum concentration is sometimes required in cases of severe kidney impairment to ensure appropriate exposure.

Q: What is the typical time frame for side effects to appear after starting Microbac?

Official safety information notes that certain serious adverse reactions, such as tendon inflammation and rupture, have a time-related pattern. These effects may occur within the first 48 hours of starting the medicine or may appear up to several months after the treatment course is completed.

Q: Does Microbac have a 'black box warning' in the US, according to the FDA?

US regulatory documents for Fluoroquinolones, the drug class Microbac belongs to, include a Boxed Warning. This warning describes the association of the drug class with disabling and potentially irreversible serious adverse reactions, such as tendon, nerve, joint, and central nervous system effects.

Q: Does Microbac show up on a standard drug screening or lab test?

Official documentation reports that Microbac may cause false-positive results for opiates when urine screening is conducted. This interference only occurs with some commercially available testing kits.

Q: Is it safe to drive or operate machinery while on Microbac?

Official safety warnings describe that caution is required regarding driving or operating machinery until an individual is certain how the medicine affects their alertness and coordination. This warning is based on the potential for Microbac to affect mental function.

Q: Does Microbac interact with birth control pills?

While specific, direct interaction is not always noted, the drug class Microbac belongs to (Fluoroquinolones) has been reported to potentially reduce the effectiveness of oral contraceptives containing certain hormonal ingredients. Regulatory guidance includes the general advice for patients to inform their healthcare provider of all medicines being used.

Q: Does Microbac have any known interactions with herbal supplements?

Regulatory guidance includes the general advice for patients to inform their healthcare provider about all other medicines, vitamins, and herbs they are taking. Herbal products may potentially interfere with the drug's absorption or effects.

Q: What is the expected timeline for improvement when using Microbac?

Official documents for certain localized uses, such as the otic solution for ear infections, provide a factual reference point. They may specify that if an infection is not improved after one week of use, further clinical evaluation is addressed in official documents.

Q: Is Microbac associated with any long-term effects on the liver or kidneys?

Official safety documents report risks of Liver injury, which may be indicated by signs such as yellowing of skin/eyes or dark urine. Furthermore, the documents note that patients with pre-existing kidney or liver disease require special caution or dose adjustment, recognizing the medicine's pathway in the body.

Q: Can I drink alcohol moderately while taking Microbac?

Official warnings state that drinking alcohol while using Microbac may increase the risk of certain side effects. Specifically, there is an increased potential for reactions that affect the central nervous system, such as dizziness or fainting spells.

Q: Can Microbac affect fertility in men or women?

Research in animal models did not show effects on male or female reproductive performance at high doses. However, human data is generally insufficient in regulatory documents to draw definitive conclusions about the medicine's potential to affect a person's ability to conceive.

Q: Is there a generic version of Microbac available?

The active ingredient in Microbac is Ofloxacin. This compound is documented by global health and regulatory bodies to be available as a generic medication.

Q: What does the drug information say about the way Microbac is eliminated from the body?

The medicine is primarily eliminated through the kidneys (renal excretion). Regulatory documents note that more than 70% of an oral dose is recovered in the urine as the unchanged drug. It has an elimination half-life of approximately five to seven hours.

How should Microbac be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal protocols for Microbac (Ofloxacin) are defined by regulatory agencies to ensure product stability and prevent misuse or environmental harm. The medicine must be stored at controlled room temperature and kept out of the reach of children.


Storage Conditions

Requirement Official Instruction
Temperature/Protection Store away from excess heat, moisture, and direct light.
Container Must be kept in the original container and be tightly closed.
Handling The ophthalmic solution must be kept from freezing.

Disposal Instructions

Expired or unused Microbac should be disposed of primarily through a drug take-back program or an authorized collection site. If no take-back program is available, the medicine must be mixed with an undesirable substance (such as dirt) and placed in a sealed bag before disposal in the household trash. The product must not be flushed down the toilet or poured down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Microbac found in:

A-Z Index: